<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864198</url>
  </required_header>
  <id_info>
    <org_study_id>RESV1</org_study_id>
    <secondary_id>3310</secondary_id>
    <nct_id>NCT03864198</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of Reveratrol,Folic Acid, Vitamin D, Vitamin B12 and B6 in Male Infertility</brief_title>
  <official_title>Evaluation of Treatment With Trans-resveratrol, Folic Acid, Vitamin D, Vitamin B12 and B6 in Men With Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ester Illiano, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the impact of the Genante(TM) on the spermiogram
      parameters in infertile male patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-centre prospective observational study. Twenty infertile male patients.

      Inclusion criteria are:

      Age:18-50 years oligozoospermia: &lt; 5 million spermatozoa/mL; asthenozoospermia: &lt; 32%
      progressive motile spermatozoa; teratozoospermia: &lt; 4% normal forms.

      Esclusion criteria:

      Patients with azoospermia, who smoke, use drugs, drugs with proven fertility toxicity,
      exposed to any environmental or occupational toxic substances, radiation or heat; with
      orchitis secondary to mumps, sexually transmitted diseases, history of cryptorchidism,
      previous testicular torsion, genitourinary anomalies, alterations of the epididymis or
      deferens; and inguinal surgery

      Pretreatment evaluation included:

      Semen analysis Hormonal determinations:follicle-stimulating hormone (FSH) and luteinising
      hormone (LH) total Testosterone Total,estradiol, prolactina, 25-OH-Vitamin D3); scrotal
      ultrasound prostatic transrectal ultrasound

      Outocmes measures (baseline, at 1 and 6 months):

        -  Semen volume (mL)

        -  Total sperm number (106/ejaculate)

        -  Sperm concentration (106/mL)

        -  Total motility (PR + NP)

        -  Progressive motility (PR, %)

        -  Vitality (live spermatozoa, %)

        -  Sperm morphology (normal forms, %)

        -  Ph

        -  FSH

        -  LH

        -  Testosterone totale

        -  Estradiol

        -  Prolactiona

        -  25-OH-Vitamin D3

        -  scrotal ultrasound

        -  prostatic transrectal ultrasound
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Semen volume at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>semen volume in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1month Semen volume at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>semen volume in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Total sperm number at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>total sperm number in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Total sperm number at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>total sperm number in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Sperm concentration at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Sperm concentration in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Sperm concentration at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Sperm concentration in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Total Motility at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>total motility of spermatozoa in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Total Motility at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>total motility of spermatozoa in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Progressive motility at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Porgressive motility of spermatozoa in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Progressive motility at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Progressive motility of spermatozoa in semen analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Vitality at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>live spermatozoa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Vitality at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>live spermatozoa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Sperm morphology at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>normal forms of spermatozoa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Sperm morphology at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>normal forms of spermatozoa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline FSH at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>plasmatic evaluation of FSH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month FSH at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>plasmatic evaluation of FSH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline LH at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Plasmatic evaluation of LH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month LH at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Plasmatic evaluation of LH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Total testosterone at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>plasmatic evaluation of total testosterone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Total testosterone at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>plasmatic evaluation of total testosterone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Prolactina at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>plasmatic evaluation of prolactina</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Prolactina at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>plasmatic evaluation of prolactina</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline 25-OH-Vitamin D3 at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>plasmatic evaluation of 25-OH-Vitamin D3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month 25-OH-Vitamin D3 at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>plasmatic evaluation of 25-OH-Vitamin D3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Scrotal ultrasound at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>testis volume and vas deferens by ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Scrotal ultrasound at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>testis volume and vas deferens by ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Trans rectal Prostatic ultrasound at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>prostate volume and morphology by ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month Trans rectal Prostatic ultrasound at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>prostate volume and morphology by ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline estradiol at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>plasmatic evaluation of esatrdiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 1 month estradiol at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>plasmatic evaluation of esatrdiol</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Genante (Tm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Genante tablets One tablet in the morning and one tablet in the evening for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Genante</intervention_name>
    <description>A dietary supplement for male infertility</description>
    <arm_group_label>Genante (Tm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male 18-50 years

          -  oligozoospermia: &lt; 5 million spermatozoa/mL;

          -  asthenozoospermia: &lt; 32% progressive motile spermatozoa;

          -  teratozoospermia: &lt; 4% normal forms.

        Exclusion Criteria:

          -  azoospermia

          -  smoke

          -  use drugs

          -  use drugs with proven fertility toxicity

          -  exposition to any environmental or occupational toxic substances

          -  exposition to radiation or heat

          -  orchitis secondary to mumps

          -  sexually transmitted diseases

          -  history of cryptorchidism

          -  previous testicular torsion

          -  genitourinary anomalies

          -  alterations of the epididymis or deferens

          -  inguinal surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Infertile man</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ester Illiano, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Of Perugia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabetta Costantini, Professor</last_name>
    <phone>3283620614</phone>
    <email>elisabetta.costantini@unipg.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ester Illiano, MD</last_name>
    <phone>3283620614</phone>
    <email>ester.illiano@inwind.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Elisabetta Costantini</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Costantini, Professor</last_name>
      <phone>3283620614</phone>
      <email>elisabetta.costantini@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>Ester Illiano, MD</last_name>
      <phone>3283620614</phone>
      <email>ester.illiano@inwind.it</email>
    </contact_backup>
    <investigator>
      <last_name>Ester Illiano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabetta Costantini, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Agarwal A, Nallella KP, Allamaneni SS, Said TM. Role of antioxidants in treatment of male infertility: an overview of the literature. Reprod Biomed Online. 2004 Jun;8(6):616-27. Review.</citation>
    <PMID>15169573</PMID>
  </reference>
  <reference>
    <citation>Griveau JF, Le Lannou D. Reactive oxygen species and human spermatozoa: physiology and pathology. Int J Androl. 1997 Apr;20(2):61-9. Review.</citation>
    <PMID>9292315</PMID>
  </reference>
  <reference>
    <citation>Aitken RJ. Free radicals, lipid peroxidation and sperm function. Reprod Fertil Dev. 1995;7(4):659-68. Review.</citation>
    <PMID>8711202</PMID>
  </reference>
  <reference>
    <citation>de Lamirande E, Leclerc P, Gagnon C. Capacitation as a regulatory event that primes spermatozoa for the acrosome reaction and fertilization. Mol Hum Reprod. 1997 Mar;3(3):175-94. Review.</citation>
    <PMID>9237244</PMID>
  </reference>
  <reference>
    <citation>Hughes CM, Lewis SE, McKelvey-Martin VJ, Thompson W. The effects of antioxidant supplementation during Percoll preparation on human sperm DNA integrity. Hum Reprod. 1998 May;13(5):1240-7. Erratum in: Hum Reprod 1998 Nov;13(11):3284.</citation>
    <PMID>9647554</PMID>
  </reference>
  <reference>
    <citation>Erben RG, Soegiarto DW, Weber K, Zeitz U, Lieberherr M, Gniadecki R, MÃ¶ller G, Adamski J, Balling R. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol. 2002 Jul;16(7):1524-37.</citation>
    <PMID>12089348</PMID>
  </reference>
  <reference>
    <citation>Hammoud AO, Meikle AW, Peterson CM, Stanford J, Gibson M, Carrell DT. Association of 25-hydroxy-vitamin D levels with semen and hormonal parameters. Asian J Androl. 2012 Nov;14(6):855-9. doi: 10.1038/aja.2012.77. Epub 2012 Oct 8.</citation>
    <PMID>23042450</PMID>
  </reference>
  <reference>
    <citation>Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertil Steril. 2002 Mar;77(3):491-8.</citation>
    <PMID>11872201</PMID>
  </reference>
  <reference>
    <citation>Chen Q, Ng V, Mei J, Chia SE. [Comparison of seminal vitamin B12, folate, reactive oxygen species and various sperm parameters between fertile and infertile males]. Wei Sheng Yan Jiu. 2001 Mar;30(2):80-2. Chinese.</citation>
    <PMID>11321956</PMID>
  </reference>
  <reference>
    <citation>Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008 Nov;25(11):2593-600. doi: 10.1007/s11095-008-9677-1. Epub 2008 Jul 16. Erratum in: Pharm Res. 2008 Dec;25(12):2983.</citation>
    <PMID>18629618</PMID>
  </reference>
  <reference>
    <citation>Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 2012 Mar 10;158(2):182-93. doi: 10.1016/j.jconrel.2011.09.083. Epub 2011 Sep 25. Review.</citation>
    <PMID>21978644</PMID>
  </reference>
  <reference>
    <citation>Orihuela-Campos RC, Tamaki N, Mukai R, Fukui M, Miki K, Terao J, Ito HO. Biological impacts of resveratrol, quercetin, and N-acetylcysteine on oxidative stress in human gingival fibroblasts. J Clin Biochem Nutr. 2015 May;56(3):220-7. doi: 10.3164/jcbn.14-129. Epub 2015 Mar 28.</citation>
    <PMID>26060353</PMID>
  </reference>
  <reference>
    <citation>Liu J, Yi L, Xiang Z, Zhong J, Zhang H, Sun T. Resveratrol attenuates spinal cord injury-induced inflammatory damage in rat lungs. Int J Clin Exp Pathol. 2015 Feb 1;8(2):1237-46. eCollection 2015.</citation>
    <PMID>25973008</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 3, 2019</last_update_submitted>
  <last_update_submitted_qc>March 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Elisabetta Costantini</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Male infertility</keyword>
  <keyword>Reveratrol</keyword>
  <keyword>Vitamin B12</keyword>
  <keyword>Vitamin B6</keyword>
  <keyword>Folic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

